<a href="https://laohu8.com/S/SLP">Simulations Plus</a> Unveils ADMET Predictor 13, Enhancing AI/ML Capabilities for Drug Discovery
Simulations Plus, Inc., a leader in cheminformatics and biosimulation solutions for the biopharma industry, has announced the release of ADMET Predictor® 13, their advanced machine learning modeling platform. This latest version enhances functionality and AI/ML capabilities, promising faster, more precise predictions in drug discovery. The platform's advancements focus on three main areas: enhanced high-throughput PBPK simulations for improved decision-making, an expanded suite of ADMET models for heightened predictive accuracy, and enterprise-ready automation features to support data-centric R&D teams. These innovations aim to streamline drug design, optimization, and selection processes, reinforcing Simulations Plus's commitment to scientific rigor and efficiency in pharmaceutical research.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simulations Plus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250605621409) on June 05, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。